Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium[68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).

Saved in:
Bibliographic Details
Title: Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium[68Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).
Authors: Khan S; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia., Papa N; Garvan Institute of Medical Research, Sydney, Australia., Kneebone A; Department of Radiation Oncology, Royal North Shore Hospital, Sydney, Australia., Eade T; Department of Radiation Oncology, Royal North Shore Hospital, Sydney, Australia., Ayati N; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, Australia., Nguyen A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, Australia., Wong K; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia., Chen J; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia., Ho B; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia., Idiare J; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia., Sidhom G; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia., Roberts MJ; Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Australia., Thompson J; Department of Urology, St. Vincent's Hospital, Sydney, Australia., Sharma S; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia., Weir S; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia., Devitt K; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia., Kooner R; Department of Urology, St. Vincent's Hospital, Sydney, Australia., Lieng H; Central Coast Cancer Centre, Gosford, New South Wales, Australia., Rasiah K; Department of Radiation Oncology, Royal North Shore Hospital, Sydney, Australia., Olphert J; Department of Urology, St George Hospital, Kogarah, NSW, Australia., de Leon J; Genesis Care, St Vincent's Hospital, Darlinghurst, NSW, Australia., Hruby G; Department of Radiation Oncology, Royal North Shore Hospital, Sydney, Australia; Genesis Care, St Vincent's Hospital, Darlinghurst, NSW, Australia., Stricker P; Garvan Institute of Medical Research, Sydney, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, Australia., Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia; Garvan Institute of Medical Research, Sydney, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, Australia. Electronic address: louise.emmett@svha.org.au.
Source: European urology [Eur Urol] 2026 Jun; Vol. 89 (6), pp. 512-520. Date of Electronic Publication: 2026 Mar 28.
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article
Journal Info: Publisher: Elsevier Science Country of Publication: Switzerland NLM ID: 7512719 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7560 (Electronic) Linking ISSN: 03022838 NLM ISO Abbreviation: Eur Urol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-7560
DOI:10.1016/j.eururo.2026.03.001